Tratamiento con sirolimus y prednisona en enfermedad de Erdheim-Chester con compromiso cardiaco: Caso clínico

• Jorge Vega ^[1] ; Mario Santamarina ^[2]
  1. [1] Hospital Naval A. Nef Servicio de medicina interna Sección nefrología
  2. [2] Hospital Naval A. Nef Servicio de radiología
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 144, Nº. 3, 2016, págs. 394-400
• Idioma: español
• Títulos paralelos:
  • Sirolimus and prednisone for the treatment of Erdheim-Chester disease with cardiac involvement: Report of one case
• Enlaces
  • Texto completo
• Resumen

  • Erdheim-Chester disease (ECD) is a rare non-Langerhans histiocytic disorder. We report a 76-years-old man who suffered a cardiac tamponade secondary to ECD. A pericardial window was made and during the operation the surgeons observed that the myocardium was diffusely infiltrated. Twenty-eight months before, ECD was clinically diagnosed and prednisone and methotrexate were prescribed. Due to disease progression which culminated in the cardiac tamponade, methotrexate was changed to sirolimus aiming to obtain plasma levels between 5-8 ng/ml. This treatment stabilized his cardiac function allowing a survival of 52 months after its initiation, with fewer side effects.